ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 168

Prevalence of Diastolic Dysfunction and Structural Heart Disease in Axial Spondyloarthritis: A Prospective Case Control Study Using Echocardiography

Risheen Reejhsinghani1, Kathryn Becker2, Nelson Schiller1, Grace Yoon3, Elyse Foster1 and Lianne S. Gensler4, 1Cardiology, University of California, San Francisco, San Francisco, CA, 2Cardiology, Kelowna General Hospital, Kelowna, BC, Canada, 3Medicine/Rheumatology, University of California, San Francisco, San Franciscao, CA, 4Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Ankylosing spondylitis (AS) and cardiovascular disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The aim of our study was to describe the prevalence of diastolic dysfunction (DD) and structural heart disease (SHD) among a cohort of Axial Spondyloarthritis (AxSpA) patients matched with a healthy control population. Aortic dilation, aortic insufficiency (AI) and DD have been reported in Ankylosing Spondylitis (AS), although their true prevalence remains uncertain. New pharmacologic therapies for AxSpA may have further impacted the prevalence of heart disease in this population. Studies to date have been small and lacked control populations, resulting in controversial recommendations for routine echocardiographic screening in AxSpA patients.

Methods: Prospective transthoracic echocardiograms were performed on 125 AxSpA patients and 56 age-matched healthy controls. Leading edge aortic root (AoR) measurements were made and normalized for body surface area. Measurements were also taken at the aortic annulus, sino-tubular junction and ascending aorta. DD was graded in accordance with the American Society of Echocardiography guidelines. Chi square tests and Wilcoxan rank sum analyses were used in the univariate analysis. A subgroup analysis was also performed in a matched group of 90 AS patients meeting the modified New York criteria and 45 healthy controls.

Results: Participants were 68% male with a mean age of 42.8±12 years. Mean AxSpA disease duration was 18.2 ± 12 years. The modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) for the overall population was 7.1±14.5 units and 9.9±16.5 units for the AS population. Mean AoR diameter was 3.29±0.36 cm for cases and 3.24±0.32 cm for controls. There was no difference in linear aortic measurements, the presence of AI or DD between the two groups. The subgroup analysis of AS patients alone did not show any differences in these outcomes when compared to controls.

Conclusion: While there are differences among individual measurements used in the assessment of diastolic function, there is no clinically relevant difference in the prevalence of DD between cases and controls. Furthermore, there is no significant increase in AoR size or in the presence of AI in AxSpA patients when compared with healthy controls. These findings are the first basis of evidence to support the current recommendations against routine echocardiographic screening in asymptomatic AxSpA patients. Future subgroup analyses should focus on the impact of pharmacologic therapies on SHD and DD in this population.

Table 1: Baseline Characteristics of the Study Population

Population Characteristics

AxSp Patients

n=125

AS Patients

n=90

Baseline disease activity (ASDAS – CRP)

2.97 ± 1.25

3.09 ±1.35

Disease activity at time of echo (ASDAS – CRP)

2.0 ± 0.89

1.99 ± 0.94

Baseline CRP (mg/L)

Reference range <6.3 mg/L

16.2 ± 22.7

13.6 ± 14.8

CRP at time of echo (mg/L)

Reference range <6.3 mg/L

5.5 ± 6.5

6.12 ± 6.84

Treatment with NSAIDs

57.2%

46%

Treatment with TNFi

52%

56%

ASDAS – Ankylosing Spondylitis Disease Activity Score, CRP – C-Reactive Protein, NSAID – Non-steroidal Anti-inflammatory Drug, TNF-i – Tumor Necrosis Factor Inhibitor

Table 2: Echocardiographic Variables in the Study Population
Variables

AxSp Patients

n=125

Controls

n=56

95% CI

p-value

AS Patients

n=90

Controls

n=45

95% CI

p-value

Mean E wave velocity cm/s

77

69.4

71.8, 76.9

0.01

76.5

69.6

71.1, 77.2

0.03

Mean A wave velocity cm/s

58.4

48

52.8, 57.4

0.00

59.9

46.4

52.5, 58.0

0.00

Mean deceleration time ms

195.3

212.9

194.6, 207.2

0.02

193.9

212.9

193.1, 207.7

0.03

Mean lateral e’ velocity cm/s

12.7

14.3

12.7, 13.8

0.02

12.6

14.5

12.6, 13.9

0.08

Mean septal e’ velocity cm/s

9.6

9.5

9.2, 10

0.77

9.5

9.6

9.0, 9.96

0.83

Diastolic dysfunction

(grade 1 and above)

22%

23%

−

0.9

27%

22%

−

0.58

AoR diameter > 1.96 Z score above predicted mean

3%

2%

-0.3, -0.05

0.97

2%

2%

-0.37, -0.4

1.00

Aortic Insufficiency

(trace and above)

45%

54%

−

0.27

49%

53%

−

0.88


Disclosure: R. Reejhsinghani, None; K. Becker, None; N. Schiller, None; G. Yoon, None; E. Foster, None; L. S. Gensler, AbbVie, Amgen, Janssen, Novartis, UCB, 5.

To cite this abstract in AMA style:

Reejhsinghani R, Becker K, Schiller N, Yoon G, Foster E, Gensler LS. Prevalence of Diastolic Dysfunction and Structural Heart Disease in Axial Spondyloarthritis: A Prospective Case Control Study Using Echocardiography [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-diastolic-dysfunction-and-structural-heart-disease-in-axial-spondyloarthritis-a-prospective-case-control-study-using-echocardiography/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-diastolic-dysfunction-and-structural-heart-disease-in-axial-spondyloarthritis-a-prospective-case-control-study-using-echocardiography/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology